At a glance
ClinicalIndex Comparison RecordPhase 1Completed· 23 enrolled
Drug / intervention
Tarlatamab +1 moredrug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
A Phase 1b Study Evaluating the Safety and Efficacy of AMG 757 in Combination With AMG 404 in Subjects With Small Cell Lung Cancer (SCLC)
In Brief
A Phase 1 clinical trial evaluating Tarlatamab and AMG 404 for Small Cell Lung Cancer. Completed, enrolled 23 participants across 17 sites in 6 countries.
Detailed Summary
The main purpose of this study is to evaluate the safety, tolerability, and recommended phase 2 target dose of tarlatamab in combination with AMG 404.
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsSmall Cell Lung Cancer
CountriesAustria, Belgium, Japan, Singapore, Taiwan, United States
Collaborators--
Timeline
Phase 1CompletedFinished
20222023202420252026
First PostedMay 2021
Enrollment StartSep 2021
Primary CompletionJul 2023
Study CompletionSep 2024
TodayJul 2026
First PostedMay 13, 2021
Enrollment StartSep 27, 2021
Primary CompletionJul 12, 2023
Study CompletionSep 11, 2024
TodayJul 2, 2026
Enrollment to primary: 1.8 yearsPosted 5.1 years ago
Interventions
Tarlatamabdrug
Tarlatamab will be administered as an intravenous (IV) infusion.
AMG 404drug
AMG 404 will be administered as an intravenous (IV) infusion.